Interventions to reduce the time to diagnosis of brain tumours.


Journal

The Cochrane database of systematic reviews
ISSN: 1469-493X
Titre abrégé: Cochrane Database Syst Rev
Pays: England
ID NLM: 100909747

Informations de publication

Date de publication:
04 09 2020
Historique:
entrez: 9 9 2020
pubmed: 10 9 2020
medline: 24 10 2020
Statut: epublish

Résumé

Brain tumours are recognised as one of the most difficult cancers to diagnose because presenting symptoms, such as headache, cognitive symptoms, and seizures, may be more commonly attributable to other, more benign conditions. Interventions to reduce the time to diagnosis of brain tumours include national awareness initiatives, expedited pathways, and protocols to diagnose brain tumours, based on a person's presenting symptoms and signs; and interventions to reduce waiting times for brain imaging pathways. If such interventions reduce the time to diagnosis, it may make it less likely that people experience clinical deterioration, and different treatment options may be available. To systematically evaluate evidence on the effectiveness of interventions that may influence: symptomatic participants to present early (shortening the patient interval), thresholds for primary care referral (shortening the primary care interval), and time to imaging diagnosis (shortening the secondary care interval and diagnostic interval). To produce a brief economic commentary, summarising the economic evaluations relevant to these interventions. For evidence on effectiveness, we searched CENTRAL, MEDLINE, and Embase from January 2000 to January 2020; Clinicaltrials.gov to May 2020, and conference proceedings from 2014 to 2018. For economic evidence, we searched the UK National Health Services Economic Evaluation Database from 2000 to December 2014. We planned to include studies evaluating any active intervention that may influence the diagnostic pathway, e.g. clinical guidelines, direct access imaging, public health campaigns, educational initiatives, and other interventions that might lead to early identification of primary brain tumours. We planned to include randomised and non-randomised comparative studies. Included studies would include people of any age, with a presentation that might suggest a brain tumour. Two review authors independently assessed titles identified by the search strategy, and the full texts of potentially eligible studies. We resolved discrepancies through discussion or, if required, by consulting another review author. We did not identify any studies for inclusion in this review. We excluded 115 studies. The main reason for exclusion of potentially eligible intervention studies was their study design, due to a lack of control groups. We found no economic evidence to inform a brief economic commentary on this topic. In this version of the review, we did not identify any studies that met the review inclusion criteria for either effectiveness or cost-effectiveness. Therefore, there is no evidence from good quality studies on the best strategies to reduce the time to diagnosis of brain tumours, despite the prioritisation of research on early diagnosis by the James Lind Alliance in 2015. This review highlights the need for research in this area.

Sections du résumé

BACKGROUND
Brain tumours are recognised as one of the most difficult cancers to diagnose because presenting symptoms, such as headache, cognitive symptoms, and seizures, may be more commonly attributable to other, more benign conditions. Interventions to reduce the time to diagnosis of brain tumours include national awareness initiatives, expedited pathways, and protocols to diagnose brain tumours, based on a person's presenting symptoms and signs; and interventions to reduce waiting times for brain imaging pathways. If such interventions reduce the time to diagnosis, it may make it less likely that people experience clinical deterioration, and different treatment options may be available.
OBJECTIVES
To systematically evaluate evidence on the effectiveness of interventions that may influence: symptomatic participants to present early (shortening the patient interval), thresholds for primary care referral (shortening the primary care interval), and time to imaging diagnosis (shortening the secondary care interval and diagnostic interval). To produce a brief economic commentary, summarising the economic evaluations relevant to these interventions.
SEARCH METHODS
For evidence on effectiveness, we searched CENTRAL, MEDLINE, and Embase from January 2000 to January 2020; Clinicaltrials.gov to May 2020, and conference proceedings from 2014 to 2018. For economic evidence, we searched the UK National Health Services Economic Evaluation Database from 2000 to December 2014.
SELECTION CRITERIA
We planned to include studies evaluating any active intervention that may influence the diagnostic pathway, e.g. clinical guidelines, direct access imaging, public health campaigns, educational initiatives, and other interventions that might lead to early identification of primary brain tumours. We planned to include randomised and non-randomised comparative studies. Included studies would include people of any age, with a presentation that might suggest a brain tumour.
DATA COLLECTION AND ANALYSIS
Two review authors independently assessed titles identified by the search strategy, and the full texts of potentially eligible studies. We resolved discrepancies through discussion or, if required, by consulting another review author.
MAIN RESULTS
We did not identify any studies for inclusion in this review. We excluded 115 studies. The main reason for exclusion of potentially eligible intervention studies was their study design, due to a lack of control groups. We found no economic evidence to inform a brief economic commentary on this topic.
AUTHORS' CONCLUSIONS
In this version of the review, we did not identify any studies that met the review inclusion criteria for either effectiveness or cost-effectiveness. Therefore, there is no evidence from good quality studies on the best strategies to reduce the time to diagnosis of brain tumours, despite the prioritisation of research on early diagnosis by the James Lind Alliance in 2015. This review highlights the need for research in this area.

Identifiants

pubmed: 32901926
doi: 10.1002/14651858.CD013564.pub2
pmc: PMC8082957
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

CD013564

Subventions

Organisme : Department of Health
ID : 16/114/18
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K02325X/1
Pays : United Kingdom

Informations de copyright

Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Références

Methods Mol Biol. 2009;472:323-42
pubmed: 19107440
Neurology. 2010 Aug 24;75(8):699-704
pubmed: 20733145
Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):484-9
pubmed: 18349266
Emerg Med J. 2002 Jan;19(1):11-6
pubmed: 11777863
Neurochirurgie. 2005 Sep;51(3-4 Pt 2):287-98
pubmed: 16292173
Arch Dis Child. 2010 Jul;95(7):534-9
pubmed: 20371594
BMC Cancer. 2019 Jun 24;19(1):616
pubmed: 31234813
Br J Cancer. 2018 Jan;118(1):24-31
pubmed: 29182609
J Clin Nurs. 2018 Aug;27(15-16):3044-3055
pubmed: 29603812
Clin Oncol (R Coll Radiol). 2008 Mar;20(2):201-2
pubmed: 18365326
J Neurol Neurosurg Psychiatry. 2004 Jun;75 Suppl 2:ii18-23
pubmed: 15146035
Neuro Oncol. 2015 Jun;17(6):776-83
pubmed: 25313193
Br J Cancer. 2011 Jun 7;104(12):1810-5
pubmed: 21610702
BMJ Open. 2018 May 24;8(5):e017593
pubmed: 29794088
Neurologia (Engl Ed). 2020 Jun;35(5):323-331
pubmed: 28870392
Pediatr Neurol. 2017 Apr;69:11-23
pubmed: 28274641
Br J Gen Pract. 2017 Jun;67(659):278-279
pubmed: 28546414
Evid Based Med. 2017 Jun;22(3):85-87
pubmed: 28320705
Neurosurgery. 2015 Jan;76(1):1-5; quiz 6
pubmed: 25255253
Dtsch Arztebl Int. 2008 Jan;105(4):55-61
pubmed: 19633770
Epilepsia. 2011 Sep;52(9):1750-6
pubmed: 21740417
Br J Cancer. 2013 Jun 11;108(11):2329-33
pubmed: 23619924
Clin Oncol (R Coll Radiol). 2003 Feb;15(1):7-9
pubmed: 12602547
Dan Med J. 2012 May;59(5):A4437
pubmed: 22549490
Br J Cancer. 2009 Dec 3;101 Suppl 2:S1-4
pubmed: 19956152
Klin Padiatr. 2018 Oct;230(6):305-313
pubmed: 29996150
Dan Med J. 2012 May;59(5):A4438
pubmed: 22549491
Indian J Pediatr. 2011 Dec;78(12):1510-9
pubmed: 21695381
J Neurol Neurosurg Psychiatry. 2006 Dec;77(12):1305-6
pubmed: 17110745
Radiologe. 2014 Aug;54(8):754-63
pubmed: 25081917
Neuro Oncol. 2016 Sep;18(9):1199-208
pubmed: 27106405
Epilepsia. 2006 Jun;47(6):952-9
pubmed: 16822241
Semin Pediatr Neurol. 2010 Jun;17(2):105-8
pubmed: 20541102
Cancer Epidemiol. 2020 Feb;64:101617
pubmed: 31810885
Strahlenther Onkol. 2017 Nov;193(11):984-988
pubmed: 28875328
Br J Neurosurg. 2012 Jun;26(3):321-4
pubmed: 22320443
Clin Oncol (R Coll Radiol). 2007 Jun;19(5):273-86
pubmed: 17517327
Ann Oncol. 2009 May;20 Suppl 4:126-8
pubmed: 19454432
BMC Neurol. 2016 Aug 26;16(1):152
pubmed: 27561306
J Clin Neurosci. 2019 Aug;66:121-127
pubmed: 31133367
Cancer. 1996 Aug 15;78(4):874-80
pubmed: 8756384
Fam Pract. 2015 Dec;32(6):618-23
pubmed: 26467645
Arq Neuropsiquiatr. 2011 Apr;69(2A):212-6
pubmed: 21537563
Neuro Oncol. 2016 Mar;18(3):445-54
pubmed: 26523066
Acta Med Croatica. 2008 Dec;62(5):501-4
pubmed: 19382633
Curr Opin Neurol. 2018 Aug;31(4):354-361
pubmed: 29952832
Pediatr Emerg Care. 2012 Feb;28(2):200-4; quiz 205-7
pubmed: 22307193
Eur Radiol. 2018 Aug;28(8):3306-3317
pubmed: 29536240
J Neurooncol. 2015 Dec;125(3):503-30
pubmed: 26530265
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
J Neurol. 2015 May;262(5):1266-70
pubmed: 25794862
Lancet Oncol. 2007 Aug;8(8):685-95
pubmed: 17644483
Br J Gen Pract. 2008 Dec;58(557):880-5
pubmed: 19068162
Fam Pract. 2018 Sep 18;35(5):551-558
pubmed: 29420713
Australas Radiol. 1999 Nov;43(4):448-50
pubmed: 10901957
Cochrane Database Syst Rev. 2012 Oct 17;10:CD004398
pubmed: 23076904
Curr Oncol. 2009 Dec;16(6):29-41
pubmed: 20016744
Hippokratia. 2008 Apr;12(2):98-102
pubmed: 18923652
Br J Cancer. 2012 Oct 9;107(8):1220-6
pubmed: 22996611
BMJ. 2016 Oct 12;355:i4919
pubmed: 27733354
Cancer Lett. 2016 Jun 1;375(2):263-273
pubmed: 26966000
Fam Pract. 1999 Apr;16(2):143-8
pubmed: 10381020
PLoS One. 2016 May 20;11(5):e0155933
pubmed: 27203083
J Accid Emerg Med. 2000 Jan;17(1):15-7
pubmed: 10658984
Acta Med Croatica. 2008 May;62(2):241-5
pubmed: 18710092
Br J Gen Pract. 2010 Dec;60(581):897-901
pubmed: 21144199
Curr Oncol Rep. 2012 Feb;14(1):48-54
pubmed: 22012633
J Neurooncol. 2008 Sep;89(3):287-311
pubmed: 18712282
Lancet Oncol. 2017 Jun;18(6):e315-e329
pubmed: 28483413
Bull Cancer. 2017 Feb;104(2):128-138
pubmed: 27939009
Acta Oncol. 2017 Mar;56(3):405-414
pubmed: 27924653
Semin Pediatr Neurol. 2010 Jun;17(2):123-33
pubmed: 20541105
J Emerg Med. 2017 Mar;52(3):299-310
pubmed: 27876328
Cureus. 2019 Feb 21;11(2):e4113
pubmed: 31058007
Clin Neurol Neurosurg. 2015 May;132:37-40
pubmed: 25764998
Neuroradiology. 2002 May;44(5):371-81
pubmed: 12012120
Br J Gen Pract. 2007 Sep;57(542):695-9
pubmed: 17761056
Scott Med J. 2009 Nov;54(4):15-9
pubmed: 20034275
Curr Pain Headache Rep. 2011 Aug;15(4):302-7
pubmed: 21400252
Br J Neurosurg. 1997 Aug;11(4):318-30
pubmed: 9337930
Cephalalgia. 2009 Dec;29(12):1311-6
pubmed: 19911465
Neurol Sci. 2004 Oct;25 Suppl 3:S196-201
pubmed: 15549536
Clin Radiol. 2005 Oct;60(10):1090-9
pubmed: 16179169
Br J Gen Pract. 2011 Nov;61(592):e700-6
pubmed: 22054333
J Neurooncol. 2015 Dec;125(3):457-79
pubmed: 26530262
BMC Fam Pract. 2019 Aug 20;20(1):118
pubmed: 31431191
Arch Dis Child Educ Pract Ed. 2013 Oct;98(5):181-5
pubmed: 23852944
Sociol Health Illn. 2018 Mar;40(3):410-425
pubmed: 29230815
J Stroke Cerebrovasc Dis. 2012 Nov;21(8):673-8
pubmed: 21482142
Br J Neurosurg. 2013 Oct;27(5):642-5
pubmed: 23472626
Dev Med Child Neurol. 2017 Jan;59(1):31-37
pubmed: 28368092
Curr Pain Headache Rep. 2014 Jun;18(6):421
pubmed: 24760490
Eur J Cancer Care (Engl). 2010 Jan 1;19(1):98-109
pubmed: 19552730
Neurology. 1985 Feb;35(2):219-26
pubmed: 3969210
Croat Med J. 2004 Apr;45(2):206-12
pubmed: 15103760
Ann Oncol. 2007 Apr;18 Suppl 2:ii69-70
pubmed: 17491055
Br J Gen Pract. 2016 Jul;66(648):e491-8
pubmed: 27215570
BMJ. 2018 Jul 17;362:k2924
pubmed: 30018066
Br J Cancer. 2013 Feb 19;108(3):686-90
pubmed: 23392082
Radiographics. 2006 Oct;26 Suppl 1:S173-89
pubmed: 17050514
Ann Emerg Med. 2014 Nov;64(5):509-15
pubmed: 24746847
Br J Gen Pract. 2019 Apr;69(681):e224-e235
pubmed: 30858332
J Clin Oncol. 2004 Jul 15;22(14):2865-72
pubmed: 15254054
Nat Rev Neurol. 2017 May;13(5):279-289
pubmed: 28387340
PLoS One. 2019 Jan 7;14(1):e0208728
pubmed: 30615622
Acute Med. 2012;11(3):144-9
pubmed: 22993744
Neuron. 2014 Jun 18;82(6):1205-8
pubmed: 24945765
Clin Neuroradiol. 2011 Sep;21(3):123-39
pubmed: 21538040
Lancet Oncol. 2014 Aug;15(9):e395-403
pubmed: 25079102
Semin Neurol. 2006 Apr;26(2):163-70
pubmed: 16628526
J Neurol Neurosurg Psychiatry. 1996 Aug;61(2):143-50
pubmed: 8708681
Bull Cancer. 2003 Oct;90(10):873-86
pubmed: 14706916
Curr Probl Pediatr Adolesc Health Care. 2017 Mar;47(3):44-65
pubmed: 28366491
Nuklearmedizin. 2011;50(4):167-73
pubmed: 21789338
BMJ Open. 2019 Aug 30;9(8):e029686
pubmed: 31471440
Acad Emerg Med. 2016 Sep;23(9):1040-7
pubmed: 27155309
Arch Dis Child. 2020 Apr;105(4):355-362
pubmed: 31653616
Neuroimaging Clin N Am. 2006 Nov;16(4):619-32, viii-ix
pubmed: 17148023
Headache. 2009 Sep;49(8):1174-85
pubmed: 19619242
Neurosurgery. 2017 May 1;80(5):816-819
pubmed: 28327977
J Neurooncol. 2015 Dec;125(3):531-49
pubmed: 26530263
PLoS One. 2019 Mar 22;14(3):e0213599
pubmed: 30901334
Lancet Neurol. 2019 Apr;18(4):376-393
pubmed: 30797715
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120
Radiol Med. 2007 Dec;112(8):1225-43
pubmed: 18074193
Dev Med Child Neurol. 2006 Dec;48(12):985-90
pubmed: 17109788

Auteurs

Robin Grant (R)

Edinburgh Centre for Neuro-Oncology (ECNO), Western General Hospital, Edinburgh, UK.

Therese Dowswell (T)

C/o Cochrane Pregnancy and Childbirth Group, Department of Women's and Children's Health, The University of Liverpool, Liverpool, UK.

Eve Tomlinson (E)

Cochrane Gynaecological, Neuro-oncology and Orphan Cancers, 1st Floor Education Centre, Royal United Hospital, Bath, UK.

Paul M Brennan (PM)

Translational Neurosurgery Department, Western General Hospital, Edinburgh, UK.

Fiona M Walter (FM)

Public Health & Primary Care, University of Cambridge, Cambridge, UK.

Yoav Ben-Shlomo (Y)

Population Health Sciences, Bristol Medical School, Bristol, UK.

David William Hunt (DW)

Foundation School/Dept of Clinical and Experimental Medicine, Royal Surrey County Hospital/University of Surrey, Guildford, UK.

Helen Bulbeck (H)

Director of Services, brainstrust, Cowes, UK.

Ashleigh Kernohan (A)

Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.

Tomos Robinson (T)

Institute of Health & Society, Newcastle University, Newcastle upon Tyne, UK.

Theresa A Lawrie (TA)

The Evidence-Based Medicine Consultancy Ltd, Bath, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH